International Stem Cell (ISCO) FCF Margin (2010 - 2025)
International Stem Cell (ISCO) posted quarterly FCF Margin of 1.35% for Q4 2025, up 1112.0% year-over-year from 0.11% in Q4 2024, and down 30.7% quarter-over-quarter from 1.94% in Q3 2025.
International Stem Cell (ISCO) FCF Margin (2010 - 2025) Analysis & Trends
International Stem Cell (ISCO) has reported FCF Margin for 16 consecutive years, with 1.35% the latest figure, recorded in Q4 2025.
- In Q4 2025, FCF Margin rose 1112.0% year-over-year to 1.35%; the TTM figure through Dec 2025 stood at 0.38% (up 130.0% YoY), while the FY2025 annual figure was 0.38%, up 130.0% from the prior year.
- FCF Margin eased to 1.35% in Q4 2025 per ISCO's latest filing, from 1.94% in the prior quarter.
- Across five years, FCF Margin topped out at 23.85% in Q2 2023 and bottomed at 23.76% in Q1 2021.
- Historically, FCF Margin has averaged 0.9% across 5 years, with a median of 1.64% in 2025.
- Annual changes were most pronounced in 2021 — FCF Margin tumbled 3487 bps — and 2022, when it surged 2928 bps.
- International Stem Cell's FCF Margin stood at 17.69% in 2021, then jumped by 118 bps to 3.25% in 2022, then soared by 162 bps to 8.52% in 2023, then tumbled by 215 bps to 9.77% in 2024, then jumped by 114 bps to 1.35% in 2025.
- Business Quant data shows ISCO's FCF Margin at 1.35% in Q4 2025, 1.94% in Q3 2025, and 13.57% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -388.28% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 25.68% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 22.62% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -22.35% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 70.82% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 41.07% |
| 10 | International Stem Cell | 4.32 Mn | 3.23 Mn | 1.46 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.35% |
| Sep 30, 2025 | 1.94% |
| Jun 30, 2025 | -13.57% |
| Mar 31, 2025 | 10.43% |
| Dec 31, 2024 | -9.77% |
| Sep 30, 2024 | 17.62% |
| Jun 30, 2024 | -4.42% |
| Mar 31, 2024 | -9.16% |
| Dec 31, 2023 | 8.52% |
| Sep 30, 2023 | 2.43% |
| Jun 30, 2023 | 23.85% |
| Mar 31, 2023 | 9.64% |
| Dec 31, 2022 | 3.25% |
| Sep 30, 2022 | 4.93% |
| Jun 30, 2022 | 9.47% |
| Mar 31, 2022 | -1.14% |
| Dec 31, 2021 | -17.69% |
| Sep 30, 2021 | -12.16% |
| Jun 30, 2021 | -19.80% |
| Mar 31, 2021 | -23.76% |